What is the longest resistance period to serputinib/serpatinib?

Selpercatinib is mainly suitable for the treatment of adult patients with locally advanced or metastatic ET fusion-positive non-small cell lung cancer (NSCLC), RET-mutated medullary thyroid carcinoma (MTC), and RET fusion-positive thyroid cancer (TC). Regarding its resistance period, studies have shown that although seputinib can produce significant therapeutic effects in the early stages of treatment, in some patients, resistance may occur after long-term use.

The occurrence time and degree of drug resistance vary depending on individual patient differences and the biological characteristics of the tumor, so it is impossible to accurately give a standard "resistance period". However, clinical research and trial data show that most patients can achieve significant treatment responses within 6 months to 12 months after starting treatment, and the effects of some patients may last more than a year.

The emergence of drug resistance is usually due to additional genetic mutations or mutations in tumor cells during treatment, resulting in the inability of seputinib to effectively inhibit the RET signaling pathway. For example, secondary mutations in the RET gene or activation of other related pathways may lead to resistance to seputinib. The development of drug resistance makes originally effective treatments ineffective, leading to tumor progression.

However, the resistance period is not absolute, and patients may have different resistance manifestations due to individual differences. In some cases, the effectiveness of treatment can be extended by adjusting the treatment regimen or combining it with other targeted drugs. Clinicians usually develop personalized treatment strategies based on the patient's response and drug resistance to delay the occurrence of drug resistance as much as possible.

In short, the resistance period to seputinib varies among individual patients. The mechanism of drug resistance may involve secondary mutations in the RET gene or activation of other related signaling pathways. Patients need regular monitoring and evaluation during treatment so that treatment strategies can be adjusted in a timely manner.

Reference:https://en.wikipedia.org/wiki/Selpercatinib